LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 830-835

  Green, Lisa J ^a   Marder, Philip ^a   Mann, Larry L ^a   Chio, Li Chun ^a   Current, William L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; CILOFUNGIN; ECHINOCANDIN B; PROPIDIUM IODIDE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDA ALBICANS; CELL SORTER; DRUG EFFICACY; DRUG POTENCY; DRUG UPTAKE; FLOW CYTOMETRY; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE;

EID: 0032940371     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.830     Document Type: Article

References (31)

1. Bartlett, M. S., W. L. Current, M. P. Goheen, C. J. Boylan, C. H. Lee, M. M. Shaw, S. F. Queener, and J. W. Smith. 1996. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 40:1811-1816.
2. Beaulieu, D., J. Tang, S. B. Yan, J. M. Vessels, J. A. Radding, and T. R. Parr, Jr. 1994. Characterization and cilofungin inhibition of solubilized Aspergillus fumigatus (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38: 937-944.
3. Current, W., and W. Turner. 1997. Echinocandin antifungal agents, p. 315-334. In W. Strohl (ed.), Biotechnology of antibiotics. Marcel Dekker, Inc., New York, N.Y.
4. Davey, H. M., and D. B. Kell. 1996. Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analyses. Microbiol. Rev. 60:641-696.
5. Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497.
6. Debono, M., W. W. Turner, L. LaGrandeur, F. J. Burkhardt, J. S. Nissen, K. K. Nichols, M. J. Rodriguez, M. J. Zweifel, D. J. Zeckner, R. S. Gordee, et al. 1995. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. 38:3271-3281.
7. Diaper, J. P., K. Tither, and C. Edwards. 1992. Rapid assessment of bacterial viability by flow cytometry. Appl. Microbiol. Biotechnol. 38:268-272.
8. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
9. Gordee, R. S., D. J. Zeckner, L. C. Howard, W. E. Alborn, Jr., and M. Debono. 1988. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann. N. Y. Acad. Sci. 544: 294-309.
10. Green, L., B. Petersen, L. Steimel, P. Haeber, and W. Current. 1994. Rapid determination of antifungal activity by flow cytometry. J. Clin. Microbiol. 32: 1088-1091.
11. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
12. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489. (Erratum, 38:2516.)
13. Lloyd, D., and A. J. Hayes. 1995. Vigour, vitality and viability of microorganisms. FEMS Microbiol. Lett. 133:1-7.
14. Martin, E., F. Maier, and S. Bhakdi. 1994. Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum. Antimicrob. Agents Chemother. 38:1331-1338.
15. Martin, E., U. Schlasius, and S. Bhakdi. 1992. Flow cytometric assay for estimating fungicidal activity of amphotericin B in human serum. Med. Microbiol. Immunol. 181:117-126.
16. Moore, C. B., K. L. Oakley, and D. W. Denning. 1997. In vitro activity of LY303366 compared with fluconazole, flucytosine and amphotericin B against Candida spp., abstr. F-67, p. 157. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Odds, F. C. 1996. Resistance of clinically important yeasts to antifungal agents. Int. J. Antimicrob. Agents 6:145-147.
18. Ordonez, J. V., and N. M. Wehman. 1995. Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay. Cytometry 22:154-157.
19. Petersen, B. H., L. Green, L. Steimel, D. Hyslop, and W. L. Current. 1993. Use of flow cytometry for determination of minimal exposure time for effective antifungal activity of LY303366 and other antifungal compounds, abstr. 362, p. 185. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.
21. Pore, R. S. 1992. Amphotericin B synergy testing by the FCST. Curr. Microbiol. 24:171-177.
22. Pore, R. S. 1990. Antibiotic susceptibility testing of Candida albicans by flow cytometry. Curr. Microbiol. 20:323-328.
23. Rennie, R., C. Sand, and S. Smith. 1996. In vitro activity of antifungal agent LY303366 against Candida species, other yeasts and Aspergillus species, abstr. F45, p. 107. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Taft, C. S., T. Stark, and C. P. Selitrennikoff. 1988. Cilofungin (LY121019) inhibits Candida albicans (1-3)-β-D-glucan synthase activity. Antimicrob. Agents Chemother. 32:1901-1903.
25. Tang, J., and T. R. Parr, Jr. 1991. W-1 solubilization and kinetics of inhibition by cilofungin of Candida albicans (1,3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 35:99-103.
26. Uzun, Ö., S. Kocagöz, Y. Çetinkaya, S. Arikan, and S. Ünal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.
27. Vanden Bossche, H., G. Willemsens, and P. Marichal. 1987. Anti-Candida drugs - the biochemical basis for their activity. Crit. Rev. Microbiol. 15:57-72.
28. Wade, J. C. 1997. Treatment of fungal and other opportunistic infections in immunocompromised patients. Leukemia 11(Suppl. 4):S38-S39.
29. Zeckner, D., T. Butler, C. Boylan, B. Boyll, Y. Lin, P. Raab, J. Schmidtke, and W. Current. 1993. LY303366, activity in a murine systemic candidiasis model, abstr. 365, p. 186. In Program and abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Zeckner, D., T. Butler, C. Boylan, B. Boyll, P. Watson, and W. Current. 1995. In vitro evaluation of LY303366 against Candida spp. clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis, abstr. F98, p. 130. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
31. Zelenitsky, S., J. Karlowsky, D. Hoban, N. Laing, T. Balko, A. Kabani, M. Turik, and G. Zhanel. 1997. Activity of an investigational echinocandin, LY303366 against fluconazole susceptible and resistant Candida albicans in a multiple dose in vitro pharmacodynamic model, abstr. F-72, p. 158. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.